Elzonris Approved for BPDCN and Sprycel Approval Expanded
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The Blood-Cancer.com team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- FDA approves tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. US Food & Drug Administration. Available at https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm629090.htm?utm_campaign=12-21-2018%20FDA%20approves%20tagraxofusp-erzs%20for%20BPDCN&utm_medium=email&utm_source=E. Accessed 1/4/19.
- FDA Approves Elzonris to Treat Rare Blood Cancer. Cure Today. Available at https://www.curetoday.com/articles/fda-approves-elzonris-to-treat-rare-blood-cancer. Accessed 1/4/19.
- FDA expands Sprycel approval to include certain children with acute lymphoblastic leukemia. Healio. Available at https://www.healio.com/hematology-oncology/leukemia/news/online/%7Bd076ee13-cf60-4cb3-9968-78d2cbf0a76f%7D/fda-expands-sprycel-approval-to-include-certain-children-with-acute-lymphoblastic-leukemia. Accessed 1/4/19.
- American Cancer Society. Acute Lymphoblastic Leukemia. Available at https://www.cancer.org/. Accessed 9/12/17.